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Abstract
Background: Cannabis is the most consumed illegal substance in France. General practitioners (GPs) are the health
professionals who are most consulted by adolescents. Brief intervention (BI) is a promising care initiative for the
consumption of cannabis, and could be a tool for GPs in caring for adolescents who consume cannabis. The aim of
the CANABIC study is to measure the impact of a BI carried out by a GP on the consumption of cannabis by
adolescents of 15 to 25 years of age.
Methods: A randomized clustered controlled trial, stratified over three areas (Auvergne, Languedoc-Roussillon, and
Rhône - Alpes), comparing an intervention group, which carries out the BI in consultation, and a control group,
which ensures routine medical care. The main assessment criterion is the consumption of cannabis by amount of
joints per month, at 12 months. The amount necessary to highlight a significant difference between the two groups
of 30% of consumption at 12 months is 250 patients (50 GPs, 5 patients per GP; risk α = 5%; power = 90%; intra-cluster
correlation coefficient ρ = 0.2; Hawthorne effect = 15%; lost to follow-up rates for GPs = 10% and for patients = 20%).
This plan is replicated for the three areas, and therefore a total of 750 patients are expected.
The secondary criteria for judgment are the associated consumption of tobacco and alcohol, the perception of the
consequences of consumption, and the driving of a vehicle following consumption.
Discussion: Research about BI for young cannabis users is underway. The aim of the CANABIC study is to validate a
BI suited to adolescents who consume cannabis, which may be performed in the general practice. This would
provide a tool for their treatment by a GP, which could be widely distributed during initial or further medical
training.
Trial registration: CANABIC is a randomized clustered trial (NCT01433692, registered 2011 Sept 12), PHRC funded:
Clinical Research Hospital Program (Governmental Fund, Health Ministry). Date first patient randomized: March 2012.
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Background
In Europe, 12.1% of people aged from 15 to 34 state that
they have consumed cannabis in the past year, vs. 16.7%
in France and 24.1% for the United States [1]. In France,
cannabis is the most consumed illegal substance [2];
39% of 15 to 16-year-olds [3] and 41.5% of 17-year-olds
[4] have previously smoked cannabis. This consumption
relates mainly to persons below 25 years of age with an
average age of experimentation of 15 [2]. Various levels
of consumption are described: recent users (used at least
once in the previous month), occasional (1 to 9 times
per year), repeated (10 uses/year to 10 uses/month),
regular (10 to 29 per month), and daily (at least once
per day) [1]. In France, in 2011, 24% of young people be-
tween 15 and 16 years of age and 25% of 17-year-olds
were recent consumers vs. 15% and 25% in 2007 [3,4].
Current data are clear about the risks of cannabis use:
social and psychiatric risks, and highway accidents after
smoking [5]. There is no consensus over the treatment
of adolescents who consume cannabis. In 2008, a review
of the literature explored the out-patient strategies used:
motivational interviewing (MI) seems to have positive
results in terms of the reduction of consumption of can-
nabis by young people of less than 18 years of age [6].
This was confirmed in 2013; cognitive-behavioural ther-
apies, MI, and family therapy enable a reduction in the
consumption of cannabis [7]. MI was described by
Miller and Rollnick in the early 1980’s [8], as a method
of interaction centred on the patient intended to modify
behaviours by working on the ambivalence of the pa-
tient, naturally generated by the prospect of change. The
period of psychological and physical development of
adolescence makes it a target that is particularly suited
to this technique. Brief intervention (BI) is a technique
for motivational counselling characterized by its short
duration. Its criteria of effectiveness are described using
the acronym FRAMES [9]: Feedback, Responsibility, Ad-
vice, Menu, Empathy, Self-efficacy. In various European
countries, trials have shown an effectiveness of BI on the
consumption of alcohol [10,11]. A Canadian and an
Australian study have shown the acceptability of BI
among consumers of cannabis [12,13], and a trend to-
wards a reduction in their consumption of cannabis
[12,13]. A trial showed a reduction in the frequency of
consumption at 3 months among young consumers who
had been given a BI [14]. However, these studies were
not undertaken in general medicine, but in facilities spe-
cialized in addiction or in school groups. A Swiss study
showed good acceptability and feasibility of BI among
general practitioners (GPs) and their young patients
[15], without demonstrating its effectiveness.
The 2008 report by the World Organization of Family
Doctors on mental health [16] stressed that the treat-
ment of addiction in primary healthcare is beneficial to
the improvement of the overall health condition of pa-
tients and reduces the social and economic costs that
are borne by patients and their carers. In France, the
structure of primary healthcare is primarily based on
GPs, who are the health professionals that are most con-
sulted by adolescents. One in seven patients consulting
general medicine is aged between 11 and 20 [17]. Fur-
thermore, for every seven patients, a GP sees one recent
consumer during consultation [18]. Recourse to the
healthcare system increases alongside increased cannabis
consumption [19].
The 2009–2012 European Union Action Plan on drugs
[20] and the 2nd French Governmental Plan (2009–
2011) [21] of the Inter-ministerial Mission for the Fight
Against Drugs and Drug-Addiction prioritised preven-
tion and the development of basic and clinical research.
The training of primary healthcare doctors and other
healthcare professionals for early identification was also
a priority area.
However, a French study in 2011 showed that only 8%
of GPs questioned adolescents on their consumption of
cannabis [22], indicating that there are difficulties on the
part of adolescents but also on the part of GPs in ad-
dressing this topic. In 2009, the authors carried out a
qualitative survey intended to identify the barriers dis-
couraging GPs from speaking about cannabis with young
patients. The majority of the 24 GPs, grouped into three
focus groups, did not speak about it because they felt in-
sufficiently trained in the identification and the treat-
ment of cannabis consumers, and did not know how to
address the topic. They were even less at ease if they had
known the adolescent for a long time. The illegal aspect
of the substance was an additional barrier to discussion.
They all lamented the trivialisation of consumption but
also deemed that it was within the remit of the private
life of a young patient.
The authors also undertook a qualitative study focus-
ing on the reluctance of adolescents to discuss their
health issues with their GP, and especially their con-
sumption of cannabis [23]. They were ambiguous with
their GP, who they perceived to be both moralizing and
the person who is responsible for addressing the topic.
They were more comfortable speaking about it if they
had known the GP for a long time and if they were alone
during the consultation.
The authors hypothesize that in France, a BI in general
medicine could enable identification of cannabis con-
sumption in adolescents and propose early treatment,
intended to reduce their consumption.
The main objective of the CANABIC study is to meas-
ure the effect at 12 months of a BI by GPs on cannabis
consumption among recent user adolescents of 15 to
25 years of age. The secondary objectives relate to the
variations in intermediate cannabis consumption at 3
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and 6 months, variation in consumption associated with
other methods of consumption (e.g., “bongs”), variations
in consumption associated with alcohol and tobacco, the
change in the perception of adolescents regarding the ef-
fects of their cannabis consumption on their personal,
social, and professional lives, and on driving following
the consumption of cannabis.
Methods
The main assessment criterion is the amount of joints
consumed per month at the 12th month following the
inclusion consultation. In the absence of consensus on
the definition of a threshold for dangerous cannabis con-
sumption, it is impossible to refer to a target level of
consumption. In the light of epidemiological data (pro-
portions of recent, repeated, regular, and daily users in
the age group 15–25 years) [1,2], we considered that
cannabis users consumed an average of 15 joints per
month. Our working hypothesis is that the intervention
will result in a 30% reduction in the stated consumption
of cannabis at 12 months (that is to say five joints per
month). The Hawthorne effect [24] was taken into ac-
count by estimating that adolescents of the control
group would reduce their consumption by 15% (i.e., two
joints per month).
A difference of 30% between the intervention group
(i.e., three joints per month) and the control group ap-
pears to be clinically relevant.
Some secondary hypotheses are reported in case report
forms (CRFs) at 3, 6, and 12 months by the GP: the
change to other methods of cannabis consumption such
as consumption by “bong” or “water pipe” and the impact
of the change in cannabis use on tobacco and alcohol
consumption.
Other secondary hypotheses are collected by a declara-
tory self-administered questionnaire completed by the
patient at the start and end of the study: how it is con-
sumed (alone or with friends, weekday or weekend,
joints or bongs), changing perceptions of the danger of
consumption for health, and driving after smoking.
Study design
It is a clustered randomized comparative multicentre trial,
stratified by region (Auvergne, Rhône-Alps, Languedoc-
Roussillon), conducted by 150 GPs, assigned to an inter-
vention group (IG) or a control group (CG) (Figure 1).
The intervention consists of a BI carried out in general
medicine. The patients are included during a consultation,
regardless of the reason for the consultation, and are mon-
itored over 12 months. Each doctor must include 5 pa-
tients, that is to say 750 patients in total; 50 doctors are
recruited in the three regions, 25 for the intervention
group and 25 for the control group.
In the three regions, all practising GPs are invited to
take part in the trial by mail. Doctors with an exclusive
specialty (e.g., acupuncture, homeopathy) and doctors
who have received specialized training in addiction treat-
ment (e.g., university degree, qualification, university
course) cannot take part in the trial.
Six coordinating doctors manage a group in each re-
gion. Their role is to make investigators continue inclu-
sions, answer their questions, and link investigators on
the ground to the main investigator.
Intervention versus usual care
Usual care
Investigators registered in the control group provide care
according to their usual practices.
Intervention
The investigators registered in the intervention group
conduct an interview according to the BI model, defined
as six key stages using the acronym FRAMES [9]:
 Feedback: returning the trial results to the patient.
 Responsibility: empower the patient by letting him
establish his program for reducing or stopping
consumption.
 Advice: advising moderation.
 Menu: discussing with the patient possible changes
to his/her consumption.
 Empathy: treating the patient with kindness.
 Self-efficacy: allow the patient to be in charge of his/
her own changes.
It is an interview outline; as this is a pragmatic trial aim-
ing to assess the impact of BI in daily clinical practice, the
delivery of the intervention is allowed to vary between
health care providers. The health care providers have the
flexibility to adapt the BI according to the patients’ needs.
The GPs of the intervention group are trained to carry
out the BI during a standard consultation through a
training day designed by the authors.
The training course was defined according to three
objectives:
 Updating the knowledge of GPs regarding cannabis:
levels of consumption, method of consumption,
harmful effects, possibility of treatment.
 Removing communication barriers in order to
facilitate discussion by returning the summary of
results of the two qualitative studies. Emphasis was
placed on contradictory beliefs, the expectations of
adolescents, and the reluctance of doctors.
 Training GPs in BI (theoretical explanation, exercise
in formulation of open-ended questions, practice
through role-playing).
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Inclusion and non-inclusion criteria
Inclusion criteria
All young persons from 15 to 25 years of age consuming
at least one joint per month for at least one year and
registered with a social security scheme are eligible for
the study (as stated in the law: Code of Public Health.
Article L1121_11).
Non-inclusion criteria
 A patient suffering from psychiatric illness and who
requires immediate specific care, at the discretion of
the attending doctor.
 A patient suffering from intellectual disabilities,
deafness, or who does not have a command of the
French language.
 A patient previously treated for withdrawal from
cannabis addiction or addiction to another
substance.
 Patients who have participated in one of the
preliminary qualitative studies.
Recruitment
In both groups, the investigators identify eligible adoles-
cents who consume cannabis by asking them the follow-
ing questions: “Do you smoke cannabis? For how long
have you smoked it? How much do you smoke?” The vol-
unteer GPs recruit the first five eligible adolescents that
they consult, regardless of the reason for their consult-
ation. Participation requires a prior consent, a guar-
antee of anonymity, and an unconditional right to
withdraw.
During this consultation, the investigators of the inter-
vention group conduct an interview using the BI tech-
nique with the eligible and voluntary adolescents.
The doctors of the two groups provide the patient with
an anonymous self-administered questionnaire to complete
during the consultation. This self-administered question-
naire makes it possible to collect additional information
such as method and times of consumption, monthly cost of
consumption, and a cannabis abuse screening trial (CAST)
score. The self-administered questionnaire is used in order
to not influence the course of the consultation with
Figure 1 Global design of the CANABIC study.
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adolescents of the control group and reduce the Hawthorne
effect.
During the follow-up consultation at 3 and 6 months,
the main assessment criterion is specified as well as
cigarette and alcohol consumption. The investigators of
the intervention group carry out a BI at each consultation.
During the final consultation at 12 months, the doctors
of the two groups provide another self-administered
questionnaire.
If the adolescent does not attend the following con-
sultation, the doctor can contact him/her by phone to
make another appointment or at least to obtain the re-
quired data. To help investigators, the coordinators send
a schedule of the consultations expected for each pa-
tient, as well as reminders to the GPs.
Randomization
The doctor’s surgery is the unit of randomization. Pa-
tients of an investigator GP are assigned to the same
group as him/her. Investigators from the same doctor’s
surgery are randomized within the same group in order
to avoid contamination bias. As the study is being car-
ried out in three regions in which behaviours in terms of
cannabis consumption and sociodemographic parame-
ters may differ, the randomization is stratified by region
and by state and is carried out using Stata, version 12
(StataCorp, College Station, USA). Taking into account
the risk of contamination generated by adolescents who
discuss the study with their peers while their doctors be-
long to different groups, collection of the name of the
school/college and the class is planned in order to evalu-
ate the possible impact of interpenetration. The same
will apply for registration with one or several associa-
tions (patients were asked about their membership in a
sports or cultural association; data was collected by GP
during consultation).
Statistical considerations
Sample size estimation
The calculation of the necessary amount of adolescents
was carried out on the basis of a variation in consump-
tion between the randomization groups of the amount
of joints at 1 year, based on data from literature relating
to the effect of a BI on alcohol consumption [10]. Given
that the published data has heterogeneous values in
terms of standard deviation associated with the quantity
of joints consumed and considering the importance of a
possible declarative bias, various simulations were car-
ried out according to the value of this standard deviation
(s = 1.5, 2, 3, 4 and 5) for 90% power and 5% two-sided
type 1 error taking into account inclusion of five patients
per GP, clustering by practice (intra-cluster correlation
considered between 0.05 to 0.20 [25,26], a 10% dropout
rate of GP and 20% of patients [27]). By considering the
results of these simulations, a minimum of 250 patients
is required to highlight a relative variation in the reduc-
tion in consumption of the amount of joints of 50% be-
tween the two groups (30% vs. 15%). This represents 50
investigators (25 in each randomization group). This de-
sign is respected in each region for an analysis stratified
by region and thus highlights a variation per region. In
total, 150 investigators (50 per region) must include 750
patients.
Statistical analyses
All data will be entered into a customized Access data-
base (Microsoft, Redmond, Wash, USA). Analyses will
be performed using Stata, version 12. All data will be an-
alyzed by intention to treat. The tests were two-sided,
with a type I error set at α = 0.05 (except for multiple
comparisons when appropriate). Baseline characteristics
(GPs and their patients) will be presented as the mean ±
standard deviation (SD) or the median (interquartile
range) for each randomization group for continuous
data and as the number of patients and associated per-
centages for categorical parameters. Hierarchical linear
regression models (mixed models) with levels for prac-
tice, individuals within practices, and repeated measure-
ments per individual have been used to estimate effects
of the intervention on number of joints smoked per
month post-baseline time points. These models (inter-
cept and slope as random effects) included an inter-
action between randomization group and time point,
and adjusted for number of joints smoked per month at
baseline, age of first consumption, gender, CAST at base-
line, socioeconomic status, and GP’s characteristics.
Intraclass correlation coefficients are presented by arm.
The secondary analyses will compare changes on be-
tween groups with random effects models: method of
consumption, supply method, perception of the effects
on health, professional life, social life, and driving under
the influence of alcohol will be also compared. This data
will be collected through a self-administered question-
naire that the patient will complete and leave at the GP’s
surgery. To assess the problem caused by missing data
(GP and patients), estimation methods developed by
Verbeke and Molenberg are proposed.
Ethical considerations
The protocol received the approval of the Comité de
Protection des Personnes (Commission for Public Safety)
SUD-EST VI of Clermont-Ferrand on March 5th, 2010.
The study is conducted in compliance with the regula-
tions on patient confidentiality (Comité consultatif sur le
traitement de l’information en matière de recherche
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dans le domaine de la Santé (Advisory Committee on
Data Processing for Matters of Research in the Field of
Healthcare) and Commission Nationale de l’Information
et des Libertés (National Commission for Data Protec-
tion) agreements). Inclusion is voluntary and subject
to strict anonymity and medical confidentiality. The
description of this design follows the CONSORT recom-
mendations for reporting on trials (http://www.consort-
statement.org). The trial has been registered on http://
clinicaltrials.gov/: NCT01433692.
Discussion
The main assessment criterion being consumption by
amount of joints smoked in each group, it is difficult to
establish a quantity of consumption for cannabis (e.g.,
shared joints, joints that are more or less ‘concentrated’).
The epidemiologic data usually quantifies consumption
by ‘use’ of cannabis: that is to say ‘the amount of times
that the adolescent has smoked’ [1,3,4]. Concordances
were established; half of recent smokers smoke one or
less than one joint per use, and 70% of them smoke two
or less. Regular or occasional smokers smoke five joints
or more per use in 30% of cases [4]. It would have been
possible to assess consumption more objectively using
biological sampling (hair samples, urine tests). However,
early treatment in general medicine requires a relation-
ship of trust between the doctor and the patient;
mandatory biological testing would have been badly re-
ceived by adolescents. The CAST score (Cannabis Abuse
Screening Test) is only assessed at the start of the study,
as it has the sole objective of detecting problematic use
of cannabis [28,29], but is not suited to measuring the
progression of consumption. It will enable comparison
of the progression of consumption in adolescents who
had an initial score which revealed harmful use and the
others. The primary and secondary criteria are collected
during the preceding month, then at 3, 6, and 12 months.
Collection during the preceding month was chosen in
order to limit memorization bias, while maintaining a
sense of overall consumption, as certain patients do not
consume cannabis regularly.
Any adolescents who consume cannabis are eligible, on
the condition that they smoke at least one joint per
month. These levels of consumption may appear highly
dispersed, but the European School Survey Project on Al-
cohol and other Drugs and the Survey on Health and
Consumption administered during the Defence Prepar-
ation Day data described correlations between quantity
consumed and certain behaviours (without causal links to
date), e.g., runaways, school absenteeism, depression, and
acts of violence. The difference in behaviour between oc-
casional and regular consumers is less significant than be-
tween occasional consumers and non-consumers [18].
These consumers thus constitute a homogeneous group
as regards behaviour. The selection of the 15–25 age
bracket appears to be relevant for carrying out a trial on
intervention on cannabis consumption. Fifteen years of
age is the average age of experimentation with cannabis,
and 25 years of age is the apex of consumption [2]. Con-
sumption is quite homogeneous; in the 19–25 age bracket,
14.6% are repeat consumers [2], and in 12–19 year olds,
16.4% are repeat consumers [3].
The participation of GPs in a study depends mainly on
the applicability of the topic to their practice, remuner-
ation, the support of the study coordinators, and the
feedback of information [30]. Lack of time and the ad-
ministrative burden are the main obstacles to the inclu-
sion and follow-up of patients by the GP [31]. The
illegal aspect of cannabis consumption in France can
also present an obstacle to the recruitment of GP inves-
tigators and the inclusion of adolescents. The Scientific
Committee of CANABIC developed a strategy relating
to doctors and patients in order to optimize inclusion
[25-31]: GPs are remunerated, the CRFs can be com-
pleted quickly and reattempts are carried out by the re-
gional coordinators. A pilot study tested the feasibility of
the study among volunteer GPs. Analysis of the difficul-
ties encountered by the investigators made it possible to
optimize certain features of the protocol through exten-
sion of the inclusion period (12 months) and the absence
of any specific qualification in addiction treatment of the
investigators. It does indeed appear that when the practi-
tioners have such a qualification, they already apply
these specific interview techniques and the training day
has little impact on them. In order to strengthen the
participation of patients, they were sensitized to the dan-
ger of cannabis to their own health and were empow-
ered, through the various stages of the BI [25].
There is currently broad consensus deeming that it is
important to identify at an early stage potentially addict-
ive behaviours in adolescents, as on the one hand pro-
gression towards cannabis dependency partly depends
on the age at which consumption begins [32], and on
the other primary prevention actions have not, to date,
demonstrated the effectiveness expected [33]. In several
studies, the BI appears to be a relevant tool in terms of
acceptability and feasibility among cannabis-using ado-
lescents [12-15]. A trial that does not demonstrate ef-
fectiveness raises the question of the homogeneity of the
BI carried out [34]. Recent trials have shown promise re-
garding the impact at 6 months of a BI carried out for
the consumption of several drugs [35,36]. Solid evidence
of the effectiveness of a BI on the reduction in cannabis
consumption remains to be found, particularly when it
is carried out by GPs. Easily accessible through ongoing
or initial training, the BI should improve the overall care
provided to adolescents who consume cannabis and are
monitored in primary care.
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Trial status
The CANABIC study is ongoing.
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